AMA Urges Caution With Use of Arthritis Tablets
AMA Vice President, Dr Mukesh Haikerwal, today urged people who are currently taking Celebrex (Celecoxib) and Mobic/Movalis (Meloxicam) arthritis tablets to have their prescriptions reviewed by the doctor who is treating them, following advice from the Therapeutic Goods Administration (TGA).
Dr Haikerwal said the TGA has reported adverse trial results of the two drugs, from the family of medicines know as Cox-2 Inhibitors.
The TGA has advised:
the review of the latest clinical trial information has shown that Celebrex and Mobic/Movalis caused an increased risk of clots in the blood vessels of the heart and of the brain (the cardiovascular system) in people who took these two drugs in doses higher than the normal dosage currently recommended in Australia
people who already have a high risk of having cardiovascular events such as heart attacks or strokes should see their doctor as soon as possible to discuss the potential risks.
Dr Haikerwal said the TGA has ordered manufacturers of these products to include a 'black box warning' on packaging to alert 'at risk' patients.
"Today's alert emphasises the need for caution when using any medications.
"The potential harm sometimes may outweigh the benefits of certain medications," Dr Haikerwal said.
Dr Haikerwal commended the TGA on its review and its rapid and extensive consultation with the medical profession and issuing of an alert to the public.
The AMA has advised its 28,000 members of the TGA alert.
Further information is available on the TGA website at www.tga.gov.au